Grigoriy Rekhtman

Statistics

Publications

Citations

1.2K

H-Index

Active since

2010

Affiliations

Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine(Current)

Khmelnytskyi National University

Medical University of Lodz

Botkin Hospital

Nizhny Novgorod Regional Clinical Hospital named after Semashko

Grigoriy Rekhtman is an author at Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine specializing in hematologic oncology, hematologic malignancy therapy, and medicine.

Publications per year

2010–2019

Publications

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

Philippe Moreau, Halyna Pylypenko, Sebastian Grosicki et al. · The Lancet Oncology · 2011 · 917 citations

Medicine, Pharmacology, Pharmacotherapy +15

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

Tadeusz Robak, Jie Jin, Halyna Pylypenko et al. · The Lancet Oncology · 2018 · 140 citations

Medicine, Hematology, Oncology +15

Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial

Thomas Elter, Liana Gercheva, Halyna Pylylpenko et al. · The Lancet Oncology · 2011 · 92 citations

Medicine, Oncology, Pharmacotherapy +15

Proposed rituximab biosimilar BCD‐020 versus reference rituximab for treatment of patients with indolent non‐Hodgkin lymphomas: An international multicenter randomized trial

I V Poddubnaya, Kamil Kaplanov, Les M. Lukavetskyy et al. · Hematological Oncology · 2019 · 15 citations

Pharmacy, Immunology, Pharmacokinetics +15

A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma

Philippe Moreau, Halyna Pylypenko, Sebastian Grosicki et al. · Blood · 2010 · 13 citations

Medicine, Pharmacology, Pharmacotherapy +15

1–5 of 6